The Zhitong Finance App learned that Giants Biotech (02367) fell by more than 3%, hitting a new low of HK$18.4 in the intraday period since listing. As of press release, it decreased by 3.24% to HK$18.51, with a turnover of HK$56.3929 million.
According to the news, Citi released a research report saying that the online sales performance of the Giants Biotech Double 11 promotion fell short of expectations. The bank lowered its profit forecast by about 11% to 17%, and the target price was lowered from HK$38.4 to HK$29.3, maintaining a “buy” rating, but it carried out negative observations for 30 days. The bank believes that the management's goal of 10% revenue growth for the full year 2026 is difficult to achieve, and expects pressure on profit margins to increase as potential operating leverage declines.
Furthermore, on November 12, MSCI announced its quarterly index adjustment results for November 2026. Among them, 38 shares, including Giant Biotech, were excluded from the MSCI China Index. The adjustments will take effect after the market closes on November 30.